# Study of Ipragliflozin in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy

Study · id `cardio:ct-nct02847091` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02847091](<https://clinicaltrials.gov/study/NCT02847091>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02847091

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 103 participants.

## Technical summary

Registry record NCT02847091. Allocation not applicable; no masking; primary purpose treatment. Start 2016-07-29 (actual); primary completion 2017-11-09 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 103 participants (enrolled count; ClinicalTrials.gov record NCT02847091, source copy `cardio:ctgov-nct02847091-2024-11-12`, retrieved 2026-10-26)
- Started: 2016-07-29 (actual) (ClinicalTrials.gov record NCT02847091, source copy `cardio:ctgov-nct02847091-2024-11-12`, retrieved 2026-10-26)
- Primary completion: 2017-11-09 (actual) (ClinicalTrials.gov record NCT02847091, source copy `cardio:ctgov-nct02847091-2024-11-12`, retrieved 2026-10-26)
- Completion: 2017-11-09 (actual) (ClinicalTrials.gov record NCT02847091, source copy `cardio:ctgov-nct02847091-2024-11-12`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT02847091, source copy `cardio:ctgov-nct02847091-2024-11-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02847091-2024-11-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study of Ipragliflozin in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Ipragliflozin
- Intervention (Drug): Insulin
- Lead sponsor: Astellas Pharma Inc
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Astellas Pharma Inc (`cardio:org-astellas-pharma-inc`)

## Provenance

Content hash: d8b4d28432e318090bec8516431a9268619439c8d5286db0c7a3cdfe16c64f1d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
